1. Scrip
  2. >>Focus On Asia

Biosimilar Guidances Expected In ‘Near Future,’ But Unnecessary, FDA Says

 
• By Nielsen Hobbs

Naming and labeling questions will likely be resolved with agency actions on pending biosimilar applications.

FDA is planning to issue several additional guidances on biosimilars in the “near future,” Sally Howard, Deputy Commissioner for Policy, Planning, Legislation And Analysis, said. But that policy work is not impacting the agency’s review of pending applications.

In fact, the user fee deadlines for the two biosimilar applications have been publically announced seem to be driving the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.